| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 31MM | -3% |
| Operating Income | -91MM | +14% |
| Operating Expenses | 122MM | +9% |
| Net Income | -81MM | +14% |
| R&D | 93MM | +13% |
| G&A | 29MM | -3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
HAYWARD, Calif., April 09, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 45,000 shares of the Company’s common stock at an exercise price per share of $16.97, which was the closing price on April 8, 2024, and restri
If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...
Arcus Biosciences Inc (NYSE:RCUS), a company focused on the discovery, development, and commercialization of cancer immunotherapies, has reported an insider sell according to the latest SEC filings.
Arcus Biosciences Inc (NYSE:RCUS), a company focused on the discovery, development, and commercialization of cancer immunotherapies, has reported an insider sell according to a recent SEC filing.
Arcus Biosciences Inc (NYSE:RCUS), a company focused on creating and developing cancer immunotherapies, has reported an insider sell according to a recent SEC filing.
HAYWARD, Calif., February 28, 2024--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in March:
Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Call Transcript February 22, 2024 Arcus Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to the Arcus Biosciences Full Year/Q4 2023 Earnings Call. My name is Elliot, and […]
The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Q4 2023 Arcus Biosciences Inc Earnings Call
Strategic Focus on High Unmet Medical Needs and Pipeline Advancements